New Delhi: India is uniquely positioned to capitalise on a global genomics revolution and a looming $300 billion patent expiry wave that is driving an aggressive wave of biopharma acquisitions, a report said on Wednesday. India is building capabilities in these fields through initiatives such as the Biopharma Shakti scheme and the Genome India Project mapping 10,000 genomes across 99 ethnic groups, the report said. The firm noted India’s domestic genomics market is growing at over 16 per cent annually and is actively building toward this moment. Across the genomics sector, companies are now using clinical genomic data to accelerate target identification at a scale no conventional research organisation could match. Venture capital deployed into biotech hit $38 billion in 2025, up 28 per cent year-on-year.